Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal women able to comply with the protocol requirements with confirmed primary invasive breast cancer whose tumours are estrogen-and/or progesterone-receptor positive~2. Clinical stage T2 or \>T2 tumours which in the investigators' opinion would not be eligible for breast-conserving surgery. The nodal status will be evaluated by palpation and/or ultrasound.~3. Postmenopausal status defined by one of the following:~   * Women with an intact uterus AND~     * ≥ 55 years of age, OR~    * \< 55 years of age without menses for the last 5 years, OR~    * \< 55 years of age and have not had menses for at least the last 12 months (but have had menses in the last 5 years) and have postmenopausal levels of follicle-stimulating hormone.~  * Women without an intact uterus AND~     * ≥ 55 years of age, OR~    * \< 55 years of age and postmenopausal levels of follicle-stimulating hormone~  * Both ovaries removed (prior to the diagnosis of breast cancer).~4. Tumour measurable by clinical examination, mammography and ultrasound~5. Adequate bone marrow function as shown by:~   * WBC ≥ 3.5 x 10\^9/L~  * ANC ≥ 1.5 x 10\^9/L~  * Platelets ≥ LLN~  * Hb \> 10 g/dL~Exclusion Criteria:~1. Multifocal disease (cancer that starts in several different sites)~2. Patients with bilateral breast tumours.~3. Patients who are eligible for breast conserving surgery.~4. Evidence of inflammatory breast cancer or distant metastasis.~5. Simultaneous anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy (including steroids), bisphosphonate therapy and radiotherapy. NOTE: Bisphosphonate therapy for osteoporosis is NOT excluded, and can be continued. Patients who have received hormone replacement therapy will NOT be excluded if it is discontinued at least 2 weeks before starting the study.~The following additional treatments are NOT allowed during the treatment phase of the study:~* Any other anti-cancer therapy~* Hormone replacement therapy.~* Estrogen cream (including any intra-vaginal preparation).~* Steroids other than creams or inhalers.~* Megestrol acetate for the treatment of hot flushes.~* Radiation therapy.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Letrozole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).